Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATOS Atossa Genetics	$0.78 -0.3%	$0.84	$0.55 ▼ $1.66	$100.75M	0.92	875,059 shs	463,680 shs
ERAS Erasca	$1.63 +3.5%	$1.48	$1.01 ▼ $3.31	$460.96M	1.07	1.40 million shs	326,910 shs
GOSS Gossamer Bio	$1.96 -0.3%	$1.56	$0.66 ▼ $2.23	$444.53M	1.96	1.94 million shs	878,391 shs
RGNX REGENXBIO	$8.74 -3.6%	$8.68	$5.03 ▼ $13.48	$441.21M	1.11	974,016 shs	285,539 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATOS Atossa Genetics	-0.74%	+1.31%	-14.72%	-19.59%	-37.09%
ERAS Erasca	-3.09%	+7.53%	+11.35%	+22.18%	-39.38%
GOSS Gossamer Bio	-0.51%	+12.64%	+35.17%	+88.46%	+137.00%
RGNX REGENXBIO	+1.46%	+14.68%	+9.95%	+1.91%	-24.06%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATOS Atossa Genetics	2.7307 of 5 stars	3.7	5.0	0.0	1.1	1.7	0.0
ERAS Erasca	2.4473 of 5 stars	3.5	1.0	0.0	2.5	2.5	0.6
GOSS Gossamer Bio	3.9126 of 5 stars	3.5	1.0	4.7	3.1	1.7	0.0
RGNX REGENXBIO	4.2389 of 5 stars	3.4	3.0	4.6	1.6	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATOS Atossa Genetics	3.33	Buy	$6.17	687.57% Upside
ERAS Erasca	3.00	Buy	$4.57	182.71% Upside
GOSS Gossamer Bio	3.00	Buy	$8.50	339.73% Upside
RGNX REGENXBIO	2.83	Moderate Buy	$28.38	222.44% Upside

Current Analyst Ratings Breakdown

Latest ATOS, GOSS, ERAS, and RGNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	RGNX REGENXBIO	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$21.00 ➝ $17.00
8/8/2025	RGNX REGENXBIO	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $37.00
8/8/2025	RGNX REGENXBIO	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$52.00
8/6/2025	GOSS Gossamer Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$4.00 ➝ $5.00
7/14/2025	GOSS Gossamer Bio	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$11.00
6/9/2025	RGNX REGENXBIO	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$52.00
6/6/2025	ATOS Atossa Genetics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.25 ➝ $7.50
6/5/2025	ATOS Atossa Genetics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$4.00
5/16/2025	GOSS Gossamer Bio	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $8.00
5/16/2025	GOSS Gossamer Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$4.00 ➝ $4.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	$0.45 per share	N/A
ERAS Erasca	N/A	N/A	N/A	N/A	$1.31 per share	N/A
GOSS Gossamer Bio	$114.70M	3.83	N/A	N/A	($0.20) per share	-9.67
RGNX REGENXBIO	$83.33M	5.33	N/A	N/A	$4.23 per share	2.08

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATOS Atossa Genetics	-$25.50M	-$0.21	N/A	N/A	N/A	N/A	-40.28%	-37.10%	N/A
ERAS Erasca	-$161.65M	-$0.45	N/A	N/A	N/A	N/A	-31.19%	-26.34%	N/A
GOSS Gossamer Bio	-$56.53M	-$0.62	N/A	N/A	N/A	-344.81%	-1,774.72%	-46.73%	N/A
RGNX REGENXBIO	-$227.10M	-$3.44	N/A	N/A	N/A	-112.70%	-66.95%	-34.14%	N/A

Latest ATOS, GOSS, ERAS, and RGNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	ATOS Atossa Genetics	-$0.06	-$0.07	-$0.01	-$0.07	N/A	N/A
8/12/2025	Q2 2025	ERAS Erasca	-$0.12	-$0.12	N/A	-$0.12	N/A	N/A
8/7/2025	Q2 2025	RGNX REGENXBIO	-$1.13	-$1.38	-$0.25	-$1.38	$40.87 million	$21.36 million
8/5/2025	Q2 2025	GOSS Gossamer Bio	-$0.18	-$0.17	+$0.01	-$0.17	$4.12 million	$11.49 million
5/15/2025	Q1 2025	GOSS Gossamer Bio	-$0.18	-$0.16	+$0.02	-$0.16	$3.95 million	$9.89 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	N/A
ERAS Erasca	N/A	N/A	N/A	N/A	N/A
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A
RGNX REGENXBIO	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATOS Atossa Genetics	N/A	9.17	12.67
ERAS Erasca	N/A	11.03	12.35
GOSS Gossamer Bio	6.70	4.40	4.40
RGNX REGENXBIO	N/A	3.13	3.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATOS Atossa Genetics	12.74%
ERAS Erasca	67.78%
GOSS Gossamer Bio	81.23%
RGNX REGENXBIO	88.08%

Insider Ownership

Company	Insider Ownership
ATOS Atossa Genetics	7.60%
ERAS Erasca	14.40%
GOSS Gossamer Bio	6.70%
RGNX REGENXBIO	12.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATOS Atossa Genetics	8	129.17 million	119.35 million	Optionable
ERAS Erasca	120	283.67 million	242.49 million	Optionable
GOSS Gossamer Bio	180	227.38 million	212.15 million	Optionable
RGNX REGENXBIO	370	50.51 million	44.05 million	Optionable

ATOS, GOSS, ERAS, and RGNX Headlines

Recent News About These Companies

XTX Topco Ltd Reduces Stake in REGENXBIO Inc. (NASDAQ:RGNX)

August 13 at 3:14 AM | marketbeat.com

Are Options Traders Betting on a Big Move in Regenxbio Stock?

August 12 at 11:32 PM | msn.com

REGENXBIO (NASDAQ:RGNX) Stock Rating Lowered by Wall Street Zen

August 11, 2025 | americanbankingnews.com

REGENXBIO's (RGNX) "Buy" Rating Reiterated at Chardan Capital

August 11, 2025 | americanbankingnews.com

REGENXBIO (NASDAQ:RGNX) Shares Pass Below 50-Day Moving Average Following Weak Earnings

August 10, 2025 | marketbeat.com

Royal Bank Of Canada Cuts REGENXBIO (NASDAQ:RGNX) Price Target to $17.00

August 10, 2025 | marketbeat.com

REGENXBIO (NASDAQ:RGNX) Downgraded to "Strong Sell" Rating by Wall Street Zen

August 10, 2025 | marketbeat.com

REGENXBIO (NASDAQ:RGNX) Given New $17.00 Price Target at Royal Bank Of Canada

August 10, 2025 | americanbankingnews.com

REGENXBIO (NASDAQ:RGNX) Stock Passes Below Fifty Day Moving Average After Earnings Miss

August 10, 2025 | americanbankingnews.com

These Analysts Just Made An Incredible Downgrade To Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Forecasts

August 9, 2025 | uk.finance.yahoo.com

Barclays Cuts REGENXBIO (NASDAQ:RGNX) Price Target to $37.00

August 9, 2025 | marketbeat.com

REGENXBIO (NASDAQ:RGNX) Given Buy Rating at Chardan Capital

August 9, 2025 | marketbeat.com

Regenxbio (RGNX) Reports Q2 Loss, Lags Revenue Estimates

August 7, 2025 | zacks.com

REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights

August 7, 2025 | prnewswire.com

REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy

August 7, 2025 | prnewswire.com

Regenxbio Q2 2025 Earnings Preview

August 7, 2025 | msn.com

REGENXBIO Publishes Preclinical Data Highlighting RGX-202’s Potential for Duchenne Muscular Dystrophy

August 1, 2025 | insidermonkey.com

GSA Capital Partners LLP Boosts Stake in REGENXBIO Inc. (NASDAQ:RGNX)

August 1, 2025 | marketbeat.com

REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights

July 31, 2025 | prnewswire.com

REGENXBIO (RGNX) Expected to Announce Quarterly Earnings on Thursday

July 31, 2025 | marketbeat.com

Cerity Partners LLC Makes New $228,000 Investment in REGENXBIO Inc. (NASDAQ:RGNX)

July 29, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ATOS, GOSS, ERAS, and RGNX Company Descriptions

Atossa Genetics NASDAQ:ATOS

$0.78 0.00 (-0.27%)

As of 02:16 PM Eastern

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Erasca NASDAQ:ERAS

$1.62 +0.06 (+3.50%)

As of 02:17 PM Eastern

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Gossamer Bio NASDAQ:GOSS

$1.96 -0.01 (-0.26%)

As of 02:17 PM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

REGENXBIO NASDAQ:RGNX

$8.74 -0.33 (-3.59%)

As of 02:17 PM Eastern

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time